Breaking News Instant updates and real-time market news.

ISRG

Intuitive Surgical

$536.00

-3.59 (-0.67%)

, JNJ

Johnson & Johnson

$134.41

0.16 (0.12%)

10:55
02/13/19
02/13
10:55
02/13/19
10:55

Intuitive Surgical thesis intact after J&J buys Auris Health, says Piper Jaffray

Piper Jaffray analyst JP McKim reiterated an Overweight rating on Intuitive Surgical (ISRG) following this morning's announcement that Johnson & Johnson (JNJ) will buy Auris Health, with "robotics visionary" Dr. Fred Moll joining J&J upon completion of the deal. In a research note to investors, McKim says the deal doesn't really change his thesis on Intuitive Surgical, and believes the price J&J is paying "shows investors how much they should be valuing ISRG's Ion platform."

ISRG

Intuitive Surgical

$536.00

-3.59 (-0.67%)

JNJ

Johnson & Johnson

$134.41

0.16 (0.12%)

  • 18

    Feb

  • 25

    Feb

  • 06

    Mar

ISRG Intuitive Surgical
$536.00

-3.59 (-0.67%)

01/14/19
PIPR
01/14/19
NO CHANGE
Target $625
PIPR
Overweight
Intuitive's Q4 results overshadowed positive China news, says Piper Jaffray
Overshadowed last week by Intuitive Surgical's "strong" preliminary Q4 results and 2019 procedure guidance were several positive updates in China, Piper Jaffray analyst JP McKim tells investors in a research note. These included the successful completion of a 63 patient SP trial by Hong Kong University, which highlighted the ability of the system to access hard to reach places and reduced incision, says the analyst. Further, he points out Intuitive's Xi system in China was cleared in December and that the company is now direct through its joint venture Intuitive-Fosun not only for Ion but for da Vinci products as well. McKim expects a ramp in Intuitive Surgical's placements throughout 2019 in China, which he believes should "further fuel above average" procedure growth in 2019 and 2020. The analyst reiterates an Overweight rating on Intuitive Surgical with a $625 price target.
01/25/19
PIPR
01/25/19
NO CHANGE
Target $625
PIPR
Overweight
Intuitive Surgical earnings selloff a buying opportunity, says Piper Jaffray
Piper Jaffray analyst JP McKim recommends using today's post-earnings selloff in shares of Intuitive Surgical as a buying opportunity. The company's 20%-28% operating expenditure growth outlook for 2019 is "likely to get all the attention and drag on the stock," McKim tells investors in a research note. If history repeats itself again, buying on the dip post the Q4 call in 2017 would have produced a 12 month return of 89% and buying last year's Q4 dip would have returned 22% over the last year, adds the analyst. He thinks Intuitive is likely being conservative "on all fronts" with its guidance and keeps an Overweight rating on the shares with a $625 price target.
01/25/19
STFL
01/25/19
NO CHANGE
Target $570
STFL
Buy
Intuitive Surgical price target lowered to $570 from $600 at Stifel
Stifel analyst Rick Wise said Intuitive Surgical's Q4 results were "as advertised," calling the company's more-intense-than anticipated 2019 operating expense growth guidance the biggest incremental update on the company's earnings conference call. The higher spending, potentially over multiple years, will require some "digestion" by the market, but this aggressive investment is "offensive" in nature and affirms the still largely untapped opportunity ahead, Wise tells investors. Given the OpEx spending guidance, Wise lowered his 2019 and 2020 EPS estimates and cut his price target on the stock to $570 from $600. While noting that the company does not provide specific EPS guidance, Wise added that based on his systems sales projections, management's provided procedure growth guidance would suggest a 2019 EPS range of $11.54-$11.83. He keeps a Buy rating on Intuitive Surgical shares.
01/25/19
CANT
01/25/19
NO CHANGE
CANT
Overweight
Intuitive Surgical spending to drive future sales growth, says Cantor Fitzgerald
Cantor Fitzgerald analyst Craig Bijou reiterates an Overweight rating on Intuitive Surgical with a $620 price target following last night's Q4 results. The company delivered 19% procedure growth, largely driven by U.S. general surgery and worldwide urology, Bijou tells investors in a research note. However, management plans to increase operating expenditures by 20%-28% in 2019, which comes as a surprise, adds the analyst. He expects investors to have an initial negative reaction to the expected significant increase in spending, but thinks the company's investments will fuel future sales growth and accelerate its pipeline.
JNJ Johnson & Johnson
$134.41

0.16 (0.12%)

01/14/19
WELS
01/14/19
NO CHANGE
Target $152
WELS
Outperform
Johnson & Johnson price target lowered to $152 from $162 at Wells Fargo
Wells Fargo analyst Larry Biegelsen lowered his price target for Johnson & Johnson to $152 from $162 ahead of quarterly results. The analyst forecasts Q4 sales of $20.1B and EPS of $1.97, versus consensus of $20.2B and $1.95, respectively. For 2019, Biegelsen expects initial guidance to be conservative based on the company's track record, and J&J to continue to target earnings to grow faster than sales. The analyst sees 5%-6% operational EPS growth as "reasonable." He reiterates an Outperform rating on the shares.
01/24/19
BARD
01/24/19
NO CHANGE
Target $155
BARD
Outperform
HCA Healthcare elevated to Fresh Pick at Baird
Baird analyst Matthew Gillmor elevated HCA Healthcare (HCA) to Fresh Pick ahead of its Q4 report. The analyst said recent commentary from UnitedHealth (UNH) and Johnson & Johnson (JNJ) suggest Q4 patient volumes remain solid, which he thinks will translate into EBITDA upside for HCA. Gillmor reiterated his Outperform rating and $155 price target on HCA Healthcare shares.
01/28/19
PIPR
01/28/19
NO CHANGE
Target $38
PIPR
Overweight
MorphoSys weakness on patent ruling a buying opportunity, says Piper Jaffray
MorphoSys (MOR) shares are indicating down 5% this morning after the U.S. District Court sided against the company and ruled three of its patents invalid in a summary judgement of its lawsuit against Johnson & Johnson's (JNJ) Janssen this weekend, Piper Jaffray analyst Danielle Brill tells investors in a research note. The analyst is not surprised by the outcome and had low expectations for MorphoSys winning the case. The invalidated patents do not impact MorphoSys' drug MOR-202, and "very little has been lost" for the company, Brill writes. As such, she recommends buying the stock on today's weakness. The analyst keeps an Overweight rating on MorphoSys with a $38 price target.
02/05/19
PIPR
02/05/19
NO CHANGE
Target $161
PIPR
Overweight
Piper says argenx cusatuzumab study could enable registration if responses hold
Piper Jaffray analyst Edward Tenthoff reiterated an Overweight rating and $161 price target on argenx (ARGX) after the company announced a collaboration agreement with Halozyme (HALO). In a research note to investors, Tenthoff says that an ongoing Phase II study of cusatuzumab, which was licensed to Janssen (JNJ) after demonstrating a 92% response rate in AML at ASH, could enable registration if responses hold. The company will host an R&D Day in NYC on May 16 to introduce ARGX-117 and also expects the company will introduce ARGX-118.

TODAY'S FREE FLY STORIES

SPN

Superior Energy

$4.43

0.165 (3.87%)

16:53
02/18/19
02/18
16:53
02/18/19
16:53
Earnings
Superior Energy reports Q4 EPS ($4.85), may not compare consensus (0.28c) »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Feb

MSG

Madison Square Garden

$291.37

0.85 (0.29%)

16:46
02/18/19
02/18
16:46
02/18/19
16:46
Periodicals
MSG denies Knicks sale talks after Bill Simmons claims otherwise »

Madison Square Garden…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WIN

Windstream

$3.37

0.2 (6.31%)

16:45
02/18/19
02/18
16:45
02/18/19
16:45
Hot Stocks
Windstream postpones release of Q4, FY18 financial results »

Windstream announced it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

UFPI

Universal Forest

$32.22

0.36 (1.13%)

16:43
02/18/19
02/18
16:43
02/18/19
16:43
Hot Stocks
Universal Forest signs agreement to acquire Wolverine Wood Products »

Universal Forest Products…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

SCI

Service Corp.

$45.96

0.56 (1.23%)

16:36
02/18/19
02/18
16:36
02/18/19
16:36
Earnings
Breaking Earnings news story on Service Corp. »

Service Corp. sees FY19…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Feb

SCI

Service Corp.

$45.96

0.56 (1.23%)

16:34
02/18/19
02/18
16:34
02/18/19
16:34
Earnings
Service Corp. reports Q4 adjusted EPS 54c, consensus 56c »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Feb

APY

Apergy

$36.84

0.92 (2.56%)

16:27
02/18/19
02/18
16:27
02/18/19
16:27
Earnings
Apergy reports Q4 adjusted EPS 36c, consensus 33c »

Reports Q4 revenue of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Feb

NAVI

Navient

$11.75

0.12 (1.03%)

16:20
02/18/19
02/18
16:20
02/18/19
16:20
Hot Stocks
Navient rejects highly conditional unsolicited 'expression of interest' »

Navient announced that it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SLCA

U.S. Silica

$14.41

-0.005 (-0.03%)

16:15
02/18/19
02/18
16:15
02/18/19
16:15
Hot Stocks
24 SandBox Logistics patent claims invalidated »

Proppant Express…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Feb

  • 28

    May

JBHT

J.B. Hunt

$113.78

1.66 (1.48%)

16:12
02/18/19
02/18
16:12
02/18/19
16:12
Hot Stocks
J.B. Hunt completes acquisition of Cory 1st Choice Home Delivery »

J.B. Hunt announced the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

  • 20

    Feb

  • 06

    Mar

CAT

Caterpillar

$136.21

3.575 (2.70%)

16:10
02/18/19
02/18
16:10
02/18/19
16:10
Hot Stocks
Caterpillar announces several officer moves »

Caterpillar announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

  • 20

    Feb

CUB

Cubic

$60.35

2.995 (5.22%)

16:07
02/18/19
02/18
16:07
02/18/19
16:07
Hot Stocks
Cubic announces semiannual dividend of 13.5c per share »

Cubic announced that its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Feb

  • 19

    Feb

  • 20

    Feb

  • 20

    Feb

  • 21

    Feb

HMC

Honda

$27.35

0.04 (0.15%)

13:11
02/18/19
02/18
13:11
02/18/19
13:11
Periodicals
Honda plan to close U.K. plant not due to Brexit, Reuters reports »

Honda plans to shut its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HMC

Honda

$27.35

0.04 (0.15%)

13:07
02/18/19
02/18
13:07
02/18/19
13:07
Periodicals
Honda to close U.K. car plant in 2022, Reuters reports »

Honda is set to announce…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LUNMF

Lundin Mining

$0.00

(0.00%)

13:04
02/18/19
02/18
13:04
02/18/19
13:04
Downgrade
Lundin Mining rating change at Goldman Sachs »

Lundin Mining downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CVR

Chicago Rivet & Machine

$28.36

0.56 (2.01%)

12:38
02/18/19
02/18
12:38
02/18/19
12:38
Hot Stocks
Chicago Rivet & Machine announces increase in quarterly cash dividend to 22c »

The Board of Directors of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DGX

Quest Diagnostics

$87.77

2.27 (2.66%)

, XRX

Xerox

$30.46

0.63 (2.11%)

12:36
02/18/19
02/18
12:36
02/18/19
12:36
Hot Stocks
Quest Diagnostics names Gabrielle Wolfson senior VP, CIO »

Quest Diagnostics (DGX)…

DGX

Quest Diagnostics

$87.77

2.27 (2.66%)

XRX

Xerox

$30.46

0.63 (2.11%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SRDX

Surmodics

$56.79

3.09 (5.75%)

12:29
02/18/19
02/18
12:29
02/18/19
12:29
Hot Stocks
Surmodics announces appointment of Timothy Arens as CFO »

Surmodics announced the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Mar

  • 06

    Mar

  • 07

    Mar

CUB

Cubic

$60.35

2.995 (5.22%)

, IBM

IBM

$138.05

1.55 (1.14%)

12:28
02/18/19
02/18
12:28
02/18/19
12:28
Hot Stocks
Cubic names IBM, Microsoft executive Kevin Eagan as Senior VP, Chief Digital »

Cubic (CUB) announced the…

CUB

Cubic

$60.35

2.995 (5.22%)

IBM

IBM

$138.05

1.55 (1.14%)

MSFT

Microsoft

$108.19

1.35 (1.26%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Feb

  • 19

    Feb

  • 20

    Feb

  • 20

    Feb

  • 21

    Feb

  • 25

    Feb

  • 03

    Mar

  • 04

    Mar

  • 06

    Mar

  • 07

    Mar

  • 18

    Mar

CGUSY

Casino Guichard Perrachon

$0.00

(0.00%)

11:50
02/18/19
02/18
11:50
02/18/19
11:50
Downgrade
Casino Guichard Perrachon rating change at Deutsche Bank »

Casino Guichard…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CPYYY

Centrica

$0.00

(0.00%)

11:46
02/18/19
02/18
11:46
02/18/19
11:46
Downgrade
Centrica rating change at Berenberg »

Centrica downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

11:15
02/18/19
02/18
11:15
02/18/19
11:15
General news
FX Summary: AUD-JPY has been the biggest mover »

FX Summary: AUD-JPY has…

MSM

MSC Industrial

$86.24

0.81 (0.95%)

11:07
02/18/19
02/18
11:07
02/18/19
11:07
Hot Stocks
MSC Industrial reports patent issued for cost-savings documentation system »

As previously reported on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

08:35
02/18/19
02/18
08:35
02/18/19
08:35
General news
Oil Action: Front-month WTI crude futures are up 1.0% »

Oil Action: Front-month…

07:00
02/18/19
02/18
07:00
02/18/19
07:00
General news
FX Update: A Dollar softening theme took hold during the London AM session »

FX Update: A Dollar…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.